ERBB2 and triple-negative breast carcinoma: HER2+ and triple negative breast cancers have the worst prognosis due to the fact that some HER2+ tumors are either non-responsive or develop resistance to anti-HER2 therapies, while triple negative cancers are non-responsive to hormonal therapies or drugs that target HER2 receptors1,2.